Enabling Access to Novel Pharmacotherapy in Amyotrophic Lateral Sclerosis
Implications for clinical development
On the quest to bring treatments to patients, it can be easy to forget it requires much more than just regulatory approval. There’s payer policies, cost to patients and caregivers…and it’s especially important to those stakeholders that you’ve captured the data necessary to show demonstrated clinical benefit. Take a disease with high rates of morbidity and mortality like ALS, and access variables become even more complicated.
How can you strategically navigate this complex environment and capture the data relevant to the many distinct stakeholders? Find out how: